Comparative Pharmacology
Head-to-head clinical analysis: CO LAV versus LAX LYTE WITH FLAVOR PACKS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CO LAV versus LAX LYTE WITH FLAVOR PACKS.
CO-LAV vs LAX-LYTE WITH FLAVOR PACKS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CO-LAV is a combination of codeine and acetylsalicylic acid (aspirin). Codeine is a prodrug that is metabolized to morphine, which acts as an agonist at mu-opioid receptors, producing analgesia. Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and providing analgesic, antipyretic, and anti-inflammatory effects.
Osmotic laxative: polyethylene glycol (PEG) retains water in the intestinal lumen, increasing stool volume and stimulating peristalsis. Electrolytes (sodium, potassium, chloride, bicarbonate) prevent electrolyte depletion.
Adults: 1 tablet (trimethoprim 80 mg/sulfamethoxazole 400 mg) orally twice daily for 5-7 days; for Pneumocystis jirovecii pneumonia, 2 tablets (160 mg/800 mg) orally every 6 hours for 21 days.
Oral: 1 to 2 packets (4 to 8 g of polyethylene glycol 3350) dissolved in 4 to 8 ounces of water once daily, as needed for constipation. Maximum: 2 packets per day.
None Documented
None Documented
Unknown
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 20 hours).
CO-LAV is not a recognized drug. Please check the drug name.
Primarily renal (30-50% unchanged) and biliary/fecal (50-70% as inactive metabolites).
Category C
Category C
Laxative/Bowel Evacuant
Laxative